Antibody Drug Conjugates |
The approval of a number
of Antibody Drug Conjugates has resulted in high demand of linker molecule
known as Antibody-drug conjugate linker and future opportunities in Antibody
Drug Conjugate market. ADCs are categorized as a novel class of therapeutics as
the process specifically identify the disease-associated cells and delete them.
The therapy derived this ability from lead molecules. The 310-pages report “Antibody
Drug Conjugates: Linker and Conjugation Technologies Market, 2019-2030” highlights
the current market landscape of ADCs linker and also provides likely future
opportunities in the market. The report also provides an in-depth
analysis of the technology based on noteworthy parameters.
Comments
Post a Comment